Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
X-KSK is a Japanese biotechnology joint venture established by Kirin Holdings, Suntory Holdings, and Kyowa Kirin. The company focuses on the research and development of high-performance, low-cost cell culture media specifically designed for the production of cultivated meat. By leveraging Kyowa Kirin's expertise in pharmaceutical-grade cell culture and Kirin/Suntory's experience in large-scale fermentation and food science, X-KSK aims to overcome the cost barriers associated with cell-based food production. The company's primary goal is to establish a sustainable and scalable supply chain for the cultivated meat industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on X&KSK.